Search clinical trials for: IDEC-114

Total 1986 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI); American Cancer Society, Inc.

Completed

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma

United States
Columbia University
National Institute on Aging (NIA)

Recruiting

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

Alzheimer Disease

United States
University of Alabama at Birmingham

Recruiting

The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

Parkinson Disease

United States
Hansa Biopharma AB

Completed

Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease

Chronic Kidney Disease

Sweden
IDEA AG

Completed

IDEA-033 Three Months Dose Finding in OA Followed by IDEA-033 Three Months Extension in OA

Osteoarthritis; Knee
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-1014-6470 in Healthy Subjects

Healthy

Netherlands
AbbVie
AbbVie

Recruiting

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE)

Diabetic Retinopathy (DR)

United States
Millennium Pharmaceuticals, Inc.

Terminated

A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)

Gastrointestinal Neoplasms; Esophageal, Stomach, Pancreas, Colon Neoplasms; Malignant Tumors of Digestive Organ; Advanced Gastrointestinal Malignancies

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
M.D. Anderson Cancer Center

Active, not recruiting

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Mayo Clinic
National Institute of Neurological Disorders and Stroke (NINDS)

Recruiting

Long-term Effects of COVID-19

COVID-19 | SAR-CoV-2

United States
Hansa Biopharma AB

Completed

A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test (Highdes)

Kidney Failure, Chronic

United States, Sweden, France
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Recurrent Mantle Cell Lymphoma | Stage III Mantle Cell Lymphoma | Stage IV Mantle Cell Lymphoma | Contiguous Stage II Mantle Cell Lymphoma | Noncontiguous Stage II Mantle Cell Lymphoma | Stage I Mantle Cell Lymphoma

United States
Northwestern University
Seagen Inc.

Terminated

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Leukemia | B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Completed

Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Bayer

Recruiting

An Observational Study Called JOIHA to Learn More About How Well the Treatment With Jivi Works to Prevent Problems With Joints in Adults With Hemophilia A (JOIHA)

Hemophilia A | Prophylaxis of Bleeding

Italy
Minerva Neurosciences

Completed

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder

Major Depressive Disorder

United States, Bulgaria, Finland, Georgia, Moldova, Republic of, Poland, Ukraine
Sensorion

Completed

Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy

Acute Unilateral Vestibulopathy (AUV)

United States, Israel, France, Korea, Republic of, Hungary, Germany, Czechia, Italy
National Institute of Mental Health (NIMH)

Terminated

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand

Dementia

United States
Microbiome Health Sciences

Completed

Tolerability Study of Panosyl-Isomaltooligosaccharides (PIMO) and a Placebo in Subjects With Heartburn

Heartburn

United States
Bausch Health Americas, Inc.
Dow Pharmaceutical Sciences

Completed

Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
AbbVie

Completed

Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants

ABBV-154

United States
Cellectar Biosciences, Inc.

Terminated

Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma

Glioblastoma

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma

Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Waldenstrom Macroglobulinemia | Refractory Waldenstrom Macroglobulinemia

United States
TetraLogic Pharmaceuticals
PPD; The Leukemia and Lymphoma Society; Veristat, Inc.; Therapeutics, Inc.

Completed

Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)

Lymphoma, T-Cell, Cutaneous

United States
Abbott Medical Devices

Withdrawn

Popliteal Artery of Treatment With Balloon Angioplasty vs. SUPERA VERITAS Peripheral Stent System (PARADIGM)

Peripheral Vascular Disease
Yale University
National Institute of Mental Health (NIMH); National Institutes of Health (NIH)

Recruiting

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy (ART)

Healthy | HIV Dementia | HIV Associated Neurocognitive Disorder | HIV Encephalitis

United States
Multitude Therapeutics Inc.

Recruiting

AMT-116 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Yale University
National Institute on Drug Abuse (NIDA)

Recruiting

SV2A Density Cannabis Use Disorder

Healthy | Cannabis Use Disorder

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

Active Moderate to Severe Graves' Orbitopathy
National Cancer Institute (NCI)

Recruiting

PT-112 in Subjects With Thymoma and Thymic Carcinoma

Thymic Epithelial Tumor | Thymic Cancer | Recurrent Thymoma

United States
NovalGen Ltd.

Recruiting

First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Non-small Cell Lung Cancer (NSCLC) | Small Lymphocytic Lymphoma | Malignant Melanoma | Chronic Lymphocytic Leukaemia

United Kingdom
AbbVie

Completed

RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)

Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | Wet Age-related Macular Degeneration

United States
National Institute of Mental Health (NIMH)

Completed

Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)

Normal Physiology

United States
Tammie L. S. Benzinger, MD, PhD

Active, not recruiting

Investigation of Inflammation Using [C-11]-CS1P1 (CS1P1)

Alzheimer Disease

United States
Hope Medicine (Nanjing) Co., Ltd

Completed

To Evaluate the Safety, Tolerability and Efficacy in Male and Female With AGA Treated With HMI-115 Over a 24-week Treatment Period

Androgenetic Alopecia

Australia
Taiho Oncology, Inc.

Terminated

TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations

Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations | Advanced or Metastatic Solid Tumors With Germline PTEN Inactivating Mutations

United States, United Kingdom, Austria, France
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Participants With Advanced Malignancies

Neoplasms

France, Belgium
JCR Pharmaceuticals Co., Ltd.

Active, not recruiting

An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II

Mucopolysaccharidosis II

Brazil
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

Subcutaneous Fat

United States
Nektar Therapeutics

Completed

A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors (NKTR-214)

Unspecified Adult Solid Tumor, Protocol Specific

United States
Abbott Medical Devices

Completed

AVJ-514 Japan Trial

Mitral Valve Regurgitation | Mitral Valve Incompetence | Mitral Insufficiency | Functional Mitral Regurgitation | Mitral Stenosis With Insufficiency

Japan
National Institute of Mental Health (NIMH)

Completed

PET Imaging of Cannabinoid CB1 Receptors Using [11C]MePPEP

Healthy

United States
Taiho Oncology, Inc.

Terminated

An Investigation of TAS-119 Monotherapy

Advanced Solid Tumors

Italy, Spain, United States, Netherlands, United Kingdom
Taiho Oncology, Inc.

Completed

A Study of TAS-116 in Patients With Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Italy
Oriental Neurosurgery Evidence-Based-Study Team

Unknown

11C-PIB PET/CT in Patients With Parkinson's Disease and Parkinsonian Dementia Syndromes

Parkinson Disease

China
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

Arrhythmia

United States

Search clinical trials for: IDEC-114

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations